What we do Akums Drugs & Pharmaceuticals Ltd is a leading Indian pharmaceutical CDMO offering diverse pharmaceutical formulations, APIs, and branded products globally with advanced manufacturing and R&D capabilities. |
Founded in 2,004 |
Market share Strong CDMO market presence with EU-GMP certified plants; expanding global export footprint and branded formulation sales. |
Problem solved Provides pharmaceutical contract development and manufacturing services, catering to global quality and regulatory requirements with a focus on innovation and cost-effective production. |
Top clients or who we serve Serves pharmaceutical companies globally (B2B) and domestic branded formulation markets (B2C). |
Key management - |
Our journey and innovations Established multiple specialized plants since 2004; first to innovate bi-layered sustained release tablets; expanded via acquisitions and new facilities up to 2025. |
Where we operate India, Europe, Africa, and emerging markets; operations include multiple plants in Uttarakhand, Himachal Pradesh, Punjab, Haryana, and a UK subsidiary. |
Top products or what we offer CDMO services, Active Pharmaceutical Ingredients (APIs), domestic and international branded formulations, nutraceuticals, injectables, hormones, dermatology products. |
Top brands - |
Raw materials needed Chemical intermediates and raw materials for APIs and formulations, including β-lactams, penems, hormones, and nutraceutical inputs. |
Raw materials supplier - |
Recurring vs cyclical contribution Majority recurring revenue from contract manufacturing and branded product sales with some cyclical price pressure in APIs. |
Our industry position One of India’s notable CDMOs with EU-GMP accreditation and expanding branded formulation presence domestically and internationally. |
Financial highlights FY 2024-25 consolidated revenue approx. INR 4,118 Cr; net profit INR 338 Cr; steady revenue with moderate profit growth post IPO in 2024. |
Geographical revenue split Exports growing, especially Europe and Africa; significant domestic revenue from branded formulations and contract manufacturing. |
Order book - |
Whats driving growth Volume growth in CDMO, international branded formulations recovery, operational leverage, new facility ramp-ups, and geographic expansion. |
Our future plans Ramping European CDMO facility by FY 2028, expanding injectable capacity, enhancing R&D pipeline, and growing export markets. |
Our green promise Committed to energy conservation, eco-friendly tech, and sustainable resource use with ongoing environmental and social responsibility initiatives. |
Our people and values Focuses on employee development, inclusion, safety, and ethical conduct supported by structured governance and training programs. |
Key challenges ahead API price pressures, regulatory compliance, competitive global CDMO market, and integration of acquired entities. |
Interesting facts Achieved over 63 times oversubscription in IPO; first in India to innovate bi-layered sustained release tablets; multiple EU-GMP accreditations. |
Risks and strategy Mitigating price volatility with portfolio rationalization; expanding high-margin CDMO and branded segments; investing in quality compliance and global facilities. |
